- Home
- ACOG
as 02-21-2025 4:00pm EST
Stocks
Alpha Cognition Inc is a commercial-stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI), for which there are currently no approved treatment options.
| Founded: | 2000 | Country: | Canada |
| Employees: | N/A | City: | VANCOUVER |
| Market Cap: | 91.6M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 101.6K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.66 - $7.00 | Next Earning Date: | 11-15-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Alpha Cognition Inc. Common Stock News
ACOG Breaking Stock News: Dive into ACOG Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Alpha Cognition Inc. (NASDAQ:ACOG) surges 13%; retail investors who own 46% shares profited along with institutions
Business Wire
10 days ago
Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease
Newsfile
23 days ago
Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG)
GlobeNewswire
a month ago
OTC Markets Group Announces Quarterly Index Performance and Rebalancing
Business Wire
a month ago
Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL
Business Wire
a month ago
Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China
Business Wire
2 months ago
Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call
Business Wire
2 months ago
Alpha Cognition Announces Partial Exercise of Over-allotment Option
Compare ACOG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACOG Alpha Cognition Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.